Over the recent decade, immunotherapies aiming at PD-1/PD-L1 axis modification have obtained a series of remarkable discoveries in prognosis improvement of arduously to-treat solid tumors and are going to enter into the clinical practice of brain tumors. This evidence concerns the gene CD274 and brain neoplasm.